231 related articles for article (PubMed ID: 18928983)
1. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
[TBL] [Abstract][Full Text] [Related]
2. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
[TBL] [Abstract][Full Text] [Related]
3. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
Rittenberg C; Newman RB; Istwan NB; Rhea DJ; Stanziano GJ
J Reprod Med; 2009 Feb; 54(2):47-52. PubMed ID: 19301566
[TBL] [Abstract][Full Text] [Related]
4. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
Rebarber A; Cleary-Goldman J; Istwan NB; Rhea DJ; Desch C; Russo-Stieglitz K; Saltzman DH
Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840
[TBL] [Abstract][Full Text] [Related]
5. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
Gonzalez-Quintero VH; Cordova YC; Istwan NB; Tudela F; Rhea DJ; Romary LM; Marimon A; Desch CN; Stanziano GJ
Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
[TBL] [Abstract][Full Text] [Related]
6. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
Coleman S; Wallace L; Alexander J; Istwan N
J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
[TBL] [Abstract][Full Text] [Related]
7. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
Barton JR; Barton LA; Istwan NB; Rhea DJ; Desch CN; Sibai BM
Am J Obstet Gynecol; 2011 Sep; 205(3):269.e1-6. PubMed ID: 22071060
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
Am J Obstet Gynecol; 2007 Sep; 197(3):262.e1-4. PubMed ID: 17826412
[TBL] [Abstract][Full Text] [Related]
9. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
[TBL] [Abstract][Full Text] [Related]
10. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
Ventolini G; Duke J; Po W; Barhan S; Rhea D; Desch C; Istwan N; Stanziano G
J Reprod Med; 2008 Sep; 53(9):667-71. PubMed ID: 18839818
[TBL] [Abstract][Full Text] [Related]
11. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery.
Rebarber A; Istwan NB; Russo-Stieglitz K; Cleary-Goldman J; Rhea DJ; Stanziano GJ; Saltzman DH
Diabetes Care; 2007 Sep; 30(9):2277-80. PubMed ID: 17563346
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
Sibai BM; Istwan NB; Palmer B; Stanziano GJ
Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
How HY; Barton JR; Istwan NB; Rhea DJ; Stanziano GJ
Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
[TBL] [Abstract][Full Text] [Related]
14. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
[TBL] [Abstract][Full Text] [Related]
15. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Odibo AO; Stamilio DM; Macones GA; Polsky D
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
[TBL] [Abstract][Full Text] [Related]
16. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate.
Rebarber A; Ferrara LA; Hanley ML; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH
Am J Obstet Gynecol; 2007 Mar; 196(3):224.e1-4. PubMed ID: 17346529
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
Lucas B; Poole-Yaeger A; Istwan N; Stanziano G; Rhea D; Mason M
Am J Perinatol; 2012 Aug; 29(7):489-96. PubMed ID: 22399213
[TBL] [Abstract][Full Text] [Related]
18. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Rozenberg P; Chauveaud A; Deruelle P; Capelle M; Winer N; Desbrière R; Perrotin F; Bohec C; Connan L; Vayssière C; Langer B; Mantel A; Azimi S; Porcher R; Azria E;
Am J Obstet Gynecol; 2012 Mar; 206(3):206.e1-9. PubMed ID: 22381603
[TBL] [Abstract][Full Text] [Related]
19. The impact of acute tocolysis on neonatal outcome in women hospitalized with preterm labor at 32 to 34 weeks' gestation.
Elliott JP; Istwan NB; Rhea DJ; Desch CN; Stanziano GJ
Am J Perinatol; 2009 Feb; 26(2):123-8. PubMed ID: 18850519
[TBL] [Abstract][Full Text] [Related]
20. Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice.
González-Quintero VH; de la Torre L; Rhea DJ; Tudela CM; Vazquez-Vera E; Desch C; Istwan NB
Am J Obstet Gynecol; 2010 Sep; 203(3):257.e1-5. PubMed ID: 20678745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
